GlassScriptPhysician profile
Clark Kensinger
NPI 1265759963
$34,991.00
in general payments reported to CMS, 2019-2025
23 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.10 · 2020: $32.31 · 2021: $3,034 · 2022: $176 · 2023: $160 · 2024: $4,646 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $26K · Travel and Lodging: $3,163 · Food and Beverage: $2,244 · Education: $7.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $26,316.90 |
| Travel and Lodging | $3,162.80 |
| Food and Beverage | $2,243.62 |
| Education | $7.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organox LTD | $22,144.37 | 2023-2025 | Metra |
| Paragonix Technologies, INC. | $4,597.99 | 2025 | Kidneyvault, Sherpapak |
| La Jolla Pharmaceutical Company | $4,240.00 | 2024 | Giapreza |
| Intuitive Surgical, INC. | $3,050.77 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $153.82 | 2024-2025 | |
| Boston Scientific Corporation | $152.22 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $125.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.98 | 2023-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $89.31 | 2020-2024 | Ocaliva |
| Veloxis Pharmaceuticals, INC. | $57.01 | 2024-2025 | Envarsus |
| Orphalan INC | $43.59 | 2023-2024 | Cuvrior |
| Alexion Pharmaceuticals, INC. | $33.86 | 2024 | Ultomiris |
| Conmed Corporation | $28.62 | 2024 | Airseal, Abc Handpieces |
| Mirum Pharmaceuticals, INC. | $24.71 | 2025 | Livmarli |
| Abbvie INC. | $24.13 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $22.91 | 2024 | |
| Madrigal Pharmaceuticals | $22.87 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $20.23 | 2024 | Iqirvo |
| Invivyd INC | $19.96 | 2025 | Pemgarda |
| Vifor Pharma, INC. | $17.10 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.85 | 2023 | Terlivaz |
| Lemaitre Vascular, INC. | $7.88 | 2023 | Anastoclip Gc 8cm (Medium) |
| Travere Therapeutics, INC. | $7.82 | 2023-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Kensinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.